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The institution of antiretroviral therapy (ART) in HIV-
infected individuals with the goal of achieving virologic 
control and restoring immunity has led to substan-
tial declines in AIDS-related complications, non-AIDS 
related morbidity, and improved survival [1]. In addition 
to the benefit provided at the individual level, it is also a 
crucial intervention to reduce HIV-transmission. Current 
treatment guidelines continue to emphasize early initia-
tion of ART among individuals presenting at any stage of 
HIV-infection regardless of their CD4 cell count [1].
There is also an overall consensus that ART should 
be initiated within the first 2 weeks in individuals with 
advanced HIV-infection presenting with an AIDS-defin-
ing opportunistic infection with the possible excep-
tion of cryptococcal meningoencephalitis. However, the 
most recent update of the treatment guidelines of the 
International Antiviral Society-USA recommend con-
sidering ART within 2 weeks of diagnosis of cryptococ-
cal meningoencephalitis in resource-rich settings where 
there is increased availability of optimal antifungal ther-
apy (amphotericin B formulations and flucytosine); and 
means to monitor and aggressively treat increased intrac-
ranial pressure [1].
Worldwide, the highest burden of CNS cryptococ-
cosis occurs in Sub-Saharan Africa and Southeast Asia, 
however, a substantial burden of disease occurs in high-
income settings [2–4]. In the US, the Southeast has the 
highest rates of AIDS-associated hospitalization and 
mortality due to cryptococcosis [5]. Restoring immune 
function by the institution of ART is a crucial interven-
tion in HIV-associated cryptococcal meningoencepha-
litis [2, 3]. We suggest that the timing of ART initiation 
should be individualized in every case considering host 
and fungal-related ones.
The intracranial life of Cryptococcus
In patients with HIV/AIDS, there are two distinct clinical 
scenarios of central nervous system (CNS) cryptococco-
sis: (a) cryptococcal meningoencephalitis or parenchymal 
presentations in the setting of advanced immunosup-
pression; and (b) cryptococcal immune reconstitution 
inflammatory syndrome (IRIS) after the initiation of ART 
(Table 1).
Cryptococcal meningoencephalitis in advanced 
HIV‑infection
Cryptococci encounters limited immunological resistance 
during its route of entry into a human host with advanced 
HIV-associated immunosuppression. Cryptococcus 
establishes pulmonary infection through inhalation of its 
spores or desiccated yeast cells [5–7]. Once it reaches the 
lung parenchyma, Cryptococci enters the bloodstream 
and travels to the CNS [5–9]. The CNS vasculature sys-
tem plays a crucial role in the mechanism of invasion 
of this fungal pathogen [9]. After large arteries from the 
carotid and vertebral circulations merge at the Circle of 
Willis, medium-size cerebral arteries branch into smaller 
pial arteries and arterioles that run along the surface of 
the brain. Pial arteries are constituted by an endothelial 
cell layer, a smooth muscle cell layer and an outer adven-
titial layer of leptomeningeal cells [10]. The adventitia is 
separated from brain tissue by the Virchow-Robin space 
as these arterioles penetrate deeper into the brain paren-
chyma (Fig. 1A). The Virchow-Robin space surround the 
walls of arteries, arterioles, veins, and venules as they 
course from the subarachnoid space and while penetrat-
ing through the brain parenchyma and plays an impor-
tant role in the drainage of interstitial fluid from the brain 
parenchyma [10].
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Cryptococci enters the cerebrospinal fluid (CSF), 
perivascular spaces, and brain parenchyma via transcel-
lular crossing of the endothelial cells of blood brain bar-
rier (BBB) but not of the blood-CSF barrier at the choroid 
plexus, and importantly, without affecting the integrity of 
the BBB [9, 11]. Other potential mechanism for entry into 
the CNS includes a “Trojan horse” whereby Cryptococcus 
enters hidden inside mononuclear cells [6]. Apparently, 
Cryptococci has avidity for the neurotransmitter-rich 
cerebral microenvironment surrounding the pial arteri-
oles penetrating the brain parenchyma and for reaching 
the safe haven of the perivascular spaces [6, 12] (Fig. 1A). 
Indeed, leptomeningeal cells around arteries and arteri-
oles in the human brain and in the subarachnoid space 
contain a high concentration of catechol-O-methyltrans-
ferase and pial arteries are densely innervated by perivas-
cular nerves [10] providing a suitable environment where 
this yeast can procure substrates to synthetize melanin 
and overcome oxidative stress and phagocytosis [6].
In patients with HIV/AIDS, surgical neuropathological 
examinations and autopsy case series have consistently 
reported large numbers of yeasts in the subarachnoid 
space (Fig.  1B) and in the perivascular spaces (gelati-
nous pseudocysts or flask abscesses), particularly along 
the lenticulostriate arteries entering the basal ganglia 
through the anterior perforated substance [13–17]. 
Additionally, these reports have consistently demon-
strated a paucity of inflammation in the meninges and 
subarachnoid space with only limited numbers of lym-
phocytes and few plasmocytes, and therefore the con-
cept of “cryptococcal meningitis” may in fact constitute 
a misnomer [13, 14]. Since pia mater separates the sub-
arachnoid space from underlying brain; and CSF from 
the interstitial fluid [18], Cryptococci likely enters differ-
ent spaces at different segments of the microvasculature 
[10]: (a) during the trajectories of pial arterioles inside 
the subarachnoid space allowing access of the yeast into 
the CSF; (b) through penetrating arterioles after the sub-
pial space allowing Cryptococci entering the perivascular 
spaces (Fig. 1C); and (c) via parenchymal capillaries that 
facilitates for this fungus, albeit in lesser degree, enter-
ing into the brain parenchyma (Fig.  1A) [10]. In sup-
port of the above pathways of invasion and pathological 
descriptions of CNS cryptococcosis, neuroimaging case 
Table 1 Differences in  the pathogenesis and  clinical manifestations of  untreated CNS cryptococcosis and  cryptococcal 
associated IRIS in patients with HIV/AIDS
Features HIV/AIDS associated central nervous system  
Cryptococcosis
Cryptococcal immune reconstitution syndrome
Pathogenesis Cryptococci crosses the microvascular endothelium of the 
blood brain barrier (BBB) of pial vessels and penetrating 
arterioles and capillaries via a transcellular pathway
There is no disruption of the blood–brain‑barrier
Polysaccharide antigen and yeast accumulation in subarach‑
noid space affecting the reabsorption process of the CSF in 
arachnoid villi
There is some evidence to suggest that the large number of 
yeasts residing in the perivascular spaces and brain paren‑
chyma may affect the drainage of interstitial fluid into the 
perivascular spaces and therefore contributing to intracranial 
hypertension
Triggered by accumulation of cryptococcal poly‑
saccharide in the subarachnoid space due to its 
decreased clearance producing rapid chemokine‑
mediated monocyte recruitment into the subarach‑
noid space leading to leptomeningitis
This immunological response is dysregulated and 
causes inadequate cryptococcal killing and clearance 
of the fungus within the central nervous system
Clinical spectrum of disease Meningoencephalitis with symptoms predominantly caused 
by increased intracranial hypertension (headache, nausea, 
decreased hearing, decreased vision, and others) and less 
frequently of meningitis (fever and meningismus)
Parenchymal forms (cryptococcomas) with symptoms of 
increased intracranial pressure and mass effect (i.e., seizures, 
brain herniation syndromes)
Cerebrospinal fluid analysis with a paucity of white cells
Cerebrospinal fluid culture with growth of Cryptococci
Meningitis manifesting in individuals receiving antifun‑
gal therapy and sudden onset of clinical neurologic 
deterioration after initiation of antiretroviral therapy 
(paradoxical IRIS)
Meningitis with increased intracranial pressure among 
individuals with HIV and already receiving ARTs 
(unmasked IRIS)
Cerebrospinal fluid analysis with a more inflammatory 
pattern (increased white cells)
Cerebrospinal fluid culture with no growth
Neuroimaging Dilated Virchow Robin spaces in T2‑weighted MRI imaging 
in basal ganglia and brain steam but in some cases also 
throughout cerebrum without evidence of leptomeningitis in 
most reported case series
In parenchymal forms, the confluence of gelatinous pseudo‑
cysts may produce cryptococcomas
Leptomeningitis in MRI (T1‑weighted images with 
contrast)
Management Antifungal therapy (induction, consolidation, suppression) and 
evacuation of CSF to reduce intracranial hypertension
Continuation of antifungal therapy
CSF evacuation if indicated
Corticosteroids
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series described dilated perivascular as punctate or oval 
hyper intense areas on T2-weighted images in the basal 
ganglia and brainstem. In some cases, high fungal bur-
den promotes confluence of gelatinous pseudocysts and 
extend into the brain parenchyma leading to appearance 
of cryptococcomas [19–23]. The fungal burden identified 
in many patients may reach a degree of more than 1 mil-
lion yeasts per milliliter of CSF, with greater CSF polysac-
charide antigen titers, and higher degrees of intracranial 
pressures Abnormal dural or leptomeningeal enhance-
ment is rarely described in these case series [8].
The spectrum of disease caused by CNS cryptococ-
cosis in advanced HIV-infection is mostly due to intrac-
ranial hypertension caused by CSF outflow obstruction 
(i.e. subacute onset of headache, nausea, vomiting, fever, 
decreased hearing, decreased vision, seizures, or altered 
mentation) and less frequently symptoms of meningeal 
inflammation [12]. The precise mechanism for ICH is not 
fully elucidated, however, a reduced rate of removal of 
CSF precipitated by CSF outflow blockage caused by dep-
osition of capsular polysaccharide and yeasts at arach-
noid villi [12, 24–31]. In addition, drainage of interstitial 
Fig. 1 A Pattern of invasion of Cryptococcus neoformans into intracranial compartments in the setting of advanced HIV‑infection*. a Arachnoid; b 
subarachnoid space; c pia mater; d brain parenchima; 1 Cryptococci exiting arteries into the subarachnoid space; 2 Cryptococci exiting pial arterioles 
into the perivascular spaces; and 3 Cryptococci exiting parenchymal capillaries (*Modified and adapted from Reference [10]). B Gram‑staining of cer‑
ebrospinal fluid (CSF) of a 32‑year old female demonstrating large number of yeasts (oil immersion 10 × 100). She presented with a 6‑week history 
of headache, episodes of confusion, and severe nausea. Her Cryptococcal antigen titer in CSF was >1:2200. She was found to be HIV‑infected with 
a CD4 cell count of 2 cells/µL. C Micrographs of brain parenchyma demonstrating Cryptococcus identified in a perivascular space (H&E staining 40× 
magnification)
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fluid into the perivascular spaces is disrupted by the large 
number of yeast present in both the perivascular spaces 
and in the brain parenchyma [18, 32, 33] (Fig.  1A). 
Some individuals may manifest with parenchymal brain 
involvement with focal neurological signs caused by 
expanding cryptococcomas [19–23]. In summary, the 
spectrum of clinical, pathological, and imaging of CNS 
cryptococcosis in the setting of HIV/AIDS reflects the 
pathological mechanism of invasion of this fungal patho-
gen leading to a high fungal burden, a paucity of inflam-
mation in the subarachnoid space and meninges, and 
substantial alterations in the dynamics of CSF and inter-
stitial fluid homeostasis resulting in increased intracra-
nial pressure [12].
Cryptococcal immune reconstitution inflammatory 
syndrome
Despite its sophisticated role, the brain is vulnerable to 
events that produce rapid increases in intracranial pres-
sure with potential devastating consequences [34]. This 
susceptibility resides in the fact that the brain is con-
tained in a rigid and rudimentary cranium that restricts 
any increase in volume including brain edema or any 
alteration of the fine balance of the production, circula-
tion or reabsorption of CSF [34, 35]. The expansion of 
one of the intracranial component (i.e., cerebrum, cer-
ebrospinal fluid or intravascular blood) is at the expense 
of a reduction in another component. In this context, 
immune recovery associated to the initiation of ART in 
patients with cryptococcal meningoencephalitis may 
sometimes precipitates an exuberant cellular and molec-
ular inflammatory battle against Cryptococci including 
components of its capsular polysaccharide [7, 8]. This 
response occurs predominantly in the subarachnoid 
space, leptomeninges, or in the Virchow-Robin spaces, 
which may disrupt the intracranial volume balance with 
potential life-threatening consequences.
With the increasing deployment and scale-up of ART 
in many settings, there is an overarching urgency to initi-
ate ART in those identified with HIV-infection including 
those with advanced immunosuppression [1]. Patients 
with AIDS presenting with cryptococcal meningoen-
cephalitis and CD4 cell counts <100 cell/µL, ART should 
be initiated as soon as possible. However, there are com-
peting risks and benefits that must be balanced. In one 
hand, starting ART within the first 2 weeks of antifungal 
therapy may paradoxically induce restoration of patho-
gen specific immunity leading to cryptococcal IRIS which 
can be detrimental in a patient population that is immu-
nologically unstable and clinically fragile [7, 8]. On the 
other hand, starting ART later may increase the chances 
of delaying fungal clearance and of the development of 
other life-threatening opportunistic infections. Crypto-
coccal associated IRIS occurs in approximately 13–30% 
of HIV-infected individuals and most cases occur in 
the first few months after initiating ART [2, 36]. Patho-
gen and host factors are important players in leading to 
IRIS: a high fungal burden and a poor proinflammatory 
response present prior to instituting ART (Cryptococcus 
neoformans promotes Th2 immune responses) [7, 8, 36]. 
In African cohorts, approximately one third of cases of 
CNS cryptococcosis present in patients already receiving 
ART. The institution of ART in this patient population 
may clinically unmask in the form of an IRIS, the previ-
ously undetected residence of Cryptococci in the CNS [7, 
8]. Therefore, prior to starting ART, screening for asymp-
tomatic cryptococcal antigenemia with lateral flow assays 
is considered best practice [8].
Cryptococcal associated IRIS is characterized by accu-
mulation of cryptococcal polysaccharide in the suba-
rachnoid space producing rapid chemokine-mediated 
monocyte recruitment into the subarachnoid space and 
CD4 cell redistribution into the CNS [2, 36]. This immu-
nological response is dysregulated and causes inad-
equate cryptococcal killing and clearance of the fungus 
within the neuraxis. Patients with HIV/AIDS and with 
high fungal burden at the time of diagnosis seem to be 
at the highest risk of IRIS, particularly with rapid res-
toration of immune activity following ART [37, 39, 40]. 
However, most of the reports of IRIS associated with 
CNS cryptococcosis appear to be meningeal involve-
ment in terms of its clinical presentation and also by 
evidence of leptomeningitis in T1-weighted contrast 
images [22]. CSF examination reveals important degrees 
of pleocytosis and high opening pressures but negative 
cultures [2, 36]. Cryptococcal associated IRIS may mani-
fest with a constellation of symptoms associated with 
leptomeningitis and intracranial hypertension [38, 39]. 
This abrupt process occurring a few weeks or months 
after the institution of ART may manifest clinically with 
clinical neurologic deterioration; and sometimes with 
seizures, visual and hearing loss, or mass effect with her-
niation. CNS cryptococcosis associated IRIS should be 
considered in patients with HIV infection meeting all or 
some of the following criteria [38]: (a) CSF culture-con-
firmed first episode of cryptococcal meningoencephali-
tis, (b) resolution of cryptococcal meningoencephalitis 
symptoms before starting ART, (3) self-reported adher-
ence to antifungal therapy and ART, (4) recurrence of 
symptoms (headache, nausea, vomiting, visual distur-
bance or others) after initiation of ART, (5) evidence of 
immunological and/or virologic response to ART, and 
(6) no alternative diagnosis found on laboratory test-
ing and repeated clinical assessment. These clinical 
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diagnostic criteria are imprecise but provide a frame-
work for clinicians to consider this diagnostic possibil-
ity. Recent evidence suggests that starting ARTs within 
1–2 weeks of diagnosis of CNS cryptococcosis is associ-
ated with excess mortality compared to starting ARTs at 
5  weeks [8, 40]. The excess of deaths in the early ART 
group appeared to be caused by cryptococcal menin-
goencephalitis and not from Cryptococcal IRIS [8, 40]. 
Although the incidence of Cryptococcal associated IRIS 
was not different in the two groups, the findings of this 
study does suggest that ART instituted within 1–2 weeks 
does not have a meaningful impact in reducing CNS 
cryptococcosis associated mortality.
We suggest that the timing of initiation of ART should 
be individualized considering host factors such as the 
degree of inflammatory response (level of CSF pleocy-
tosis and C-reactive protein level) and the fungal burden 
(cryptococcal antigen in CSF at the time of diagnosis and 
initial opening pressure); or assessing the sterilization of 
CSF at the end of the second week of optimal antifungal 
therapy. We believe that starting ART at 5 weeks or later 
should be considered particularly for those patients with: 
(a) extremely low CD4 cell counts; (b) cryptococcosis 
unveiling previously undiagnosed HIV infection; (c) CSF 
culture positive at 2 weeks despite standard antifungal 
treatment; and d) among those with high fungal burden 
as suggested by initial high opening pressure combined 
with cryptococcal antigen titer in CSF > 1:1056 [37].
Globally, AIDS-associated cryptococcal meningoen-
cephalitis is a deadly disease causing approximately 
20–25% of HIV-related mortality [2]. The initiation of 
fungicidal therapy with amphotericin B and flucytosine 
“stirs the pot” in the affected CNS areas (Fig. 1A) by pro-
moting cell death and releasing large amounts of capsular 
polysaccharide. During the induction phase of antifungal 
therapy, efforts should focus on ensuring optimal medi-
cal management and ensuring sterilization of CSF while 
aggressively managing intracranial hypertension with 
CSF drainage. In this context, deferring ART for 5 weeks 
or longer, may offer a margin of safety to reduce the 
chances of IRIS occurring in the confined space of the 
cranium.
Finally, the persistent occurrence of cryptococcal infec-
tion in individuals with HIV-infection living in high-
income settings unveils two major concerns: (a) the large 
number, in some settings, of undiagnosed cases of HIV 
infection who are unaware of their infection; and (b) the 
complex interplay of individual, social, and healthcare 
barriers facing individuals living with HIV-infection to 
enter into the HIV continuum of care.
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